Authors’ conclusion in the abstract | p-value | |||
---|---|---|---|---|
Control superior | Neutral | Treatment superior | ||
Number of studies | 16 | 58 | 18 | |
Comparator | ||||
Placebo/nothing: 49 studies (%) | 12 (24) | 29 (59) | 8 (16) | 0.15a |
Standard/active comparator: 43 studies (%) | 4 (9) | 29 (67) | 10 (23) | |
Funding | ||||
Industry: 37 studies (%) | 9 (24) | 21 (57) | 7 (19) | 0.14a |
Mixed: 35 studies (%) | 7 (20) | 20 (57) | 8 (23) | |
Public: 20 studies (%) | 0 | 17 (85) | 3 (15) | |
Point estimate | ||||
Median (interquartile range) | 0.99 (0.96–1.09) | 0.95 (0.90–1.01) | 0.88 (0.83–0.98) | 0.006b |
Point estimate >0.94: 48 studies (%) | 14 (29) | 29 (60) | 5 (10) | 0.002a |
Point estimate ≤0.94: 44 studies (%) | 2 (5) | 29 (66) | 13 (30) | |
Lower confidence interval | ||||
Median (interquartile range) | 0.84 (0.73–0.89) | 0.79 (0.66–0.86) | 0.66 (0.57–0.69) | 0.005b |
Confidence interval >0.75: 51 studies (%) | 11 (22) | 37 (73) | 3 (6) | 0.001a |
Confidence interval ≤0.75: 41 studies (%) | 5 (12) | 21 (51) | 15 (37) |